Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259]
In development
Reference number: GID-TA10981
Expected publication date:
Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during late September 2024 when we will write to you about how you can get involved.